Pfizer’s Ultra-Long-Acting Injectable GLP-1 RA Shows Robust and Continued Weight Loss with Monthly Dosing in Phase 2b Trial

Pfizer's Experimental Weight Loss Drug Shows Promise as a Once-a-Month Shot

In Phase II data released this week, people taking a monthly dose of PF’3944 continued to lose more weight than those on a placebo.

Data for Pfizer’s Monthly Injectable GLP-1 Drug Pave Way for Broad Phase 3 Plan in Obesity

A monthly injectable GLP-1 drug from Pfizer’s $10 billion Metsera acquisition is now on track for a Phase 3 program spanning 10 pivotal studies this year. While Pfizer’s pipeline spans internally developed and in-licensed assets for other targets, the pharma company says the Metsera drug is the foundation for its obesity strategy pursuing monotherapies and combination treatments. The post Data for Pfizer’s Monthly Injectable GLP-1 Drug Pave Way …

Pfizer dips on new data for obesity drug acquired in $10B deal

A long-acting shot Pfizer got through a buyout of Metsera appeared “slightly inferior” to Lilly’s market-leading Zepbound in a Phase 2 trial, one analyst said.

Pharmalittle: We're reading about a Pfizer obesity pill, Florida's failed drug importation plan, and more

Dozens of states are suing Novartis, alleging it conspired with other drugmakers to artificially drive up generic drug prices across the U.S.

Pfizer says obesity injection shows promise as monthly treatment in mid-stage trial

The data on Pfizer's GLP-1 offer early evidence that the injection can be administered less frequently than existing drugs without sacrificing efficacy.

Pfizer’s Ultra-Long-Acting Injectable GLP-1 RA Shows Robust and Continued Weight Loss with Monthly Dosing in Phase 2b Trial

NEW YORK--(BUSINESS WIRE)--Feb 3, 2026-